Form 4: Myriad Genetics CTO Awarded Performance Shares

Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.

Summary

• Kevin Richard Haas, Chief Technology Officer of Myriad Genetics Inc. (MYGN), reported an acquisition of 23,697 shares of common stock.
• The acquisition occurred on February 2, 2026, and increased his direct beneficial ownership to 202,332 shares.
• These shares are performance-based restricted stock units (PSUs) initially granted on March 15, 2023.
• The final award amount was determined by the Compensation and Human Capital Committee of the Company's Board of Directors on February 2, 2026, based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of the Company's common stock and is scheduled to vest on March 15, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates the achievement of internal performance metrics and reinforces management's alignment with shareholder interests through performance-based compensation.

Positives

• The award of performance-based restricted stock units indicates that the company's pre-determined performance metrics were met, suggesting operational success.
• This compensation structure aligns the interests of the Chief Technology Officer with those of shareholders, as the award is contingent on company performance.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the scheduled vesting date of the PSUs.

Industry Context

StockSavvy.ai notes that performance-based equity awards, such as PSUs, are a standard practice in the biotechnology and diagnostics industry. This approach is designed to incentivize executive leadership to achieve strategic and financial goals, thereby aligning their compensation with long-term shareholder value creation. The vesting of such awards typically signals the successful attainment of pre-defined corporate objectives.

Comparison to Industry Standards

• Performance-based compensation is a common practice across the S&P 500, with many companies, including peers in the diagnostics sector like Exact Sciences (EXAS) and Guardant Health (GH), utilizing similar equity incentive structures to motivate executives.
• The structure of Myriad Genetics' PSU award, tied to specific performance metrics and a future vesting date, is consistent with best practices for executive retention and performance alignment seen in companies like Illumina (ILMN) and Thermo Fisher Scientific (TMO).

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests that the company has met certain internal performance targets, which could be viewed positively as it indicates operational success and aligns executive incentives with shareholder value.
• Employees (specifically the CTO): The award represents a significant component of the Chief Technology Officer's compensation, rewarding past performance and incentivizing continued contributions.

Next Steps

• The 23,697 shares of common stock are scheduled to vest on March 15, 2026.

Key Dates

Keywords

MYRIAD GENETICS, MYGN, Form 4, Insider Transaction, Restricted Stock Units, PSU, Executive Compensation, Kevin Richard Haas, Performance Metrics